Benchmark Cuts CapsoVision (NASDAQ:CV) Price Target to $10.00

CapsoVision (NASDAQ:CV) had its price target lowered by Benchmark from $14.00 to $10.00 in a research report report published on Friday,Benzinga reports. Benchmark currently has a speculative buy rating on the stock.

A number of other research firms have also recently commented on CV. Wall Street Zen upgraded CapsoVision to a “hold” rating in a research note on Saturday, January 10th. Weiss Ratings reiterated a “sell (e)” rating on shares of CapsoVision in a report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, CapsoVision has a consensus rating of “Moderate Buy” and a consensus price target of $8.50.

CapsoVision Stock Performance

CapsoVision stock opened at $7.51 on Friday. The company’s 50 day simple moving average is $5.58 and its 200-day simple moving average is $6.29. The company has a market capitalization of $351.79 million and a price-to-earnings ratio of -3.43. CapsoVision has a 1 year low of $3.43 and a 1 year high of $15.37.

CapsoVision (NASDAQ:CV) last posted its quarterly earnings data on Thursday, March 26th. The company reported $0.02 earnings per share for the quarter. The company had revenue of $3.92 million for the quarter.

Hedge Funds Weigh In On CapsoVision

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC grew its position in shares of CapsoVision by 34.1% during the fourth quarter. Geode Capital Management LLC now owns 154,264 shares of the company’s stock worth $1,649,000 after buying an additional 39,231 shares in the last quarter. State Street Corp raised its holdings in CapsoVision by 340.7% in the fourth quarter. State Street Corp now owns 85,929 shares of the company’s stock valued at $919,000 after acquiring an additional 66,429 shares in the last quarter. Citadel Advisors LLC purchased a new position in CapsoVision in the third quarter worth approximately $115,000. Millennium Management LLC acquired a new position in CapsoVision during the 4th quarter worth approximately $163,000. Finally, Virtu Financial LLC acquired a new position in CapsoVision during the 4th quarter worth approximately $128,000.

CapsoVision Company Profile

CapsoVision, Inc (NASDAQ: CV) is a medical device company specializing in advanced capsule endoscopy systems for gastrointestinal diagnostics. The company’s flagship product, the CapsoCam® Plus System, features a swallowable, tether-free capsule equipped with four side-viewing cameras that capture high-resolution, 360-degree images of the small intestine. By storing images internally rather than transmitting data wirelessly, CapsoCam Plus enables patients to maintain normal daily activities during the procedure and reduces the risk of signal loss or image drop-out.

In addition to its capsule hardware, CapsoVision offers CapsoCloud®, a secure, cloud-based platform that streamlines image retrieval, storage and reporting.